AR060795A1 - CHEMICAL MOLECULES FUSED TO MATRILINA 1, FOR THERAPEUTIC USE - Google Patents

CHEMICAL MOLECULES FUSED TO MATRILINA 1, FOR THERAPEUTIC USE

Info

Publication number
AR060795A1
AR060795A1 ARP070101321A ARP070101321A AR060795A1 AR 060795 A1 AR060795 A1 AR 060795A1 AR P070101321 A ARP070101321 A AR P070101321A AR P070101321 A ARP070101321 A AR P070101321A AR 060795 A1 AR060795 A1 AR 060795A1
Authority
AR
Argentina
Prior art keywords
fused
therapeutic use
matrilina
protein
chemical molecules
Prior art date
Application number
ARP070101321A
Other languages
Spanish (es)
Inventor
Rivero Iraldo Bello
Roche Diamile Gonzalez
Cowley Jorge Victor Gavilondo
Meireles Rolando Paez
Nunez Anazuria Martinez
Santiago Glay Chinea
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR060795A1 publication Critical patent/AR060795A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Moléculas quiméricas fusionadas al péptido correspondiente al extremo carboxilo-de la Matrilina 1 humana mediante un espaciador flexible que les confiere un mayor tiempo de vida media en sangre y una actividad específica superior respecto a las moléculas no fusionadas. Reivindicacion 1: Proteína quimérica caracterizada porque contiene esencialmente el extremo carboxilo de la Matrilina 1, identificada en el listado de secuencias como Seq. ID. N°:19 desde el aminoácido numero 206 hasta el 246, y una proteína de uso terapéutico, fusionadas mediante un espaciador aminoacídico, la cual tiene una vida media y una actividad específica mayor que la proteína de uso terapéutico no fusionada.Chimeric molecules fused to the peptide corresponding to the carboxyl-end of human Matrilin 1 by means of a flexible spacer that gives them a longer half-life in blood and a specific specific activity over non-fused molecules. Claim 1: Chimeric protein characterized in that it essentially contains the carboxyl end of Matrilin 1, identified in the sequence listing as Seq. ID. N °: 19 from amino acid number 206 to 246, and a protein for therapeutic use, fused by an amino acid spacer, which has a half-life and a specific activity greater than the protein for non-fused therapeutic use.

ARP070101321A 2006-03-29 2007-03-29 CHEMICAL MOLECULES FUSED TO MATRILINA 1, FOR THERAPEUTIC USE AR060795A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060073 2006-03-29

Publications (1)

Publication Number Publication Date
AR060795A1 true AR060795A1 (en) 2008-07-16

Family

ID=38510311

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101321A AR060795A1 (en) 2006-03-29 2007-03-29 CHEMICAL MOLECULES FUSED TO MATRILINA 1, FOR THERAPEUTIC USE

Country Status (2)

Country Link
AR (1) AR060795A1 (en)
WO (1) WO2007110001A2 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0635029A4 (en) * 1992-04-10 1996-01-24 Gen Hospital Corp Cartilage matrix protein and methods for use.
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
CU23228A1 (en) * 2002-04-29 2007-09-26 Ct Ingenieria Genetica Biotech FRAGMENTS OF SPECIFIC ANTIBODIES FOR THE HUMAN CARCINOEMBRIONARY ANTIGEN (CEA) SEQUENCES OF ITS VARIABLE REGIONS AND VECTORS FOR THE MICROBIAL EXPRESSION OF THE SAME
US7081443B2 (en) * 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
FR2856070A1 (en) * 2003-06-13 2004-12-17 Bionexis New targeted therapeutic agent, useful for treatment of tumors and inflammation, comprises targeting, therapeutic and oligomerization segments, where oligomerization is essential for activity

Also Published As

Publication number Publication date
WO2007110001A3 (en) 2007-11-15
WO2007110001A2 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
PE20090225A1 (en) FUSION PROTEINS DEGRADING BETA AMYLOID PEPTIDE
UY31123A1 (en) NATURAL FUSION PROTEINS
PE20240015A1 (en) GDF15 FUSION PROTEINS AND USES OF THESE
PE20090711A1 (en) CONSTANT REGION OF MUTANT ANTIBODY
CL2013003634A1 (en) Complex comprising a fusion protein comprising, a viral peptide, linker peptide, beta 2 microglobulin, linker peptide, extracellular domains alpha 1, 2 and 3 of mhc class i and a third linker peptide; Method of production; pharmaceutical formulation that includes it; and its use
AR062030A1 (en) EXENDINE FUSION PROTEINS
MD3292141T2 (en) Fusion proteins
JP2014525901A5 (en)
AR062065A1 (en) HUMANIZED ANTIBODY
RU2016101711A (en) HIGH STABLE T-CELL RECEPTOR AND METHOD FOR ITS PRODUCTION AND APPLICATION
RU2016146198A (en) THERAPEUTIC DLL4-BINDING PROTEINS
DK1761553T3 (en) MHC molecule-binding tumor-associated peptides
ES2571879T3 (en) TNFSF single chain molecules
RU2014101697A (en) Glucagon receptor coagonists / GLP-1
JP2014524908A5 (en)
ES2676499T3 (en) Fc fusion proteins comprising new linkers or arrangements
WO2013075066A3 (en) Variant serum albumin with improved half -life and other properties
NO20071592L (en) GLP-1 and exendin-related invention
ATE474917T1 (en) METHOD FOR INCREASE IN VIVO RECOVERY OF THERAPEUTIC POLYPEPTIDES
AR044776A1 (en) GLP-1 ANALOG FUSION PROTEINS
AR055406A1 (en) SEQUENCES OF NUCLEOTIDES CODING INSECTED PROTEINS CRY1
CO6561836A2 (en) AGONIST POLYPEPTIDES THAT LINK TO DR5
AR060862A1 (en) FUSION RAGE PROTEINS, FORMULATIONS AND METHODS OF USE OF THESE
NO20082510L (en) A method for concentration of a polypeptide
PE20170142A1 (en) FUSION PROTEIN INHIBITING ANGIOGENESIS OR GROWTH AND USE OF THE SAME

Legal Events

Date Code Title Description
FA Abandonment or withdrawal